ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

Phase 2

Conditions: Autism Spectrum Disorder (ASD)
Phelan-McDermid Syndrome

Interventions: Drug: Saline
Drug: Growth Hormone

First Posted Date: 2022-01-11

Last Posted Date: 2024-05-10

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 45

Registration Number: NCT05187377

Locations: 🇺🇸
Seaver Autism Center for Research & Treatment, New York, New York, United States

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Not Applicable

Withdrawn

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions: Device: BeCare application

First Posted Date: 2021-12-29

Last Posted Date: 2022-11-25

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Registration Number: NCT05172466

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States

Environmental Factors and Thyroid Cancer

Recruiting

Conditions: Thyroid Cancer

First Posted Date: 2021-12-29

Last Posted Date: 2024-08-19

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 500

Registration Number: NCT05172921

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder

Not Applicable

Suspended

Conditions: Obsessive Compulsive Disorder (OCD)

Interventions: Device: Selective focal stimulation of ALIC-pathways

First Posted Date: 2021-12-16

Last Posted Date: 2024-08-16

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT05160129

Locations: 🇺🇸
Mount Sinai West, New York, New York, United States

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF

Phase 4

Recruiting

Conditions: Congestion
Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Ertugliflozin
Drug: Placebo

First Posted Date: 2021-12-10

Last Posted Date: 2023-10-13

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 28

Registration Number: NCT05152940

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Gondola Mechanism of Action

Not Applicable

Withdrawn

Conditions: Chronic Stroke
Cerebral Palsy
Parkinson's Disease

Interventions: Device: Gondola AMPS

First Posted Date: 2021-12-07

Last Posted Date: 2023-01-18

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Registration Number: NCT05146648

Locations: 🇺🇸
Abilities Research Center, New York, New York, United States

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Not Applicable

Recruiting

Conditions: Breast Cancer
Prostate Cancer
Liver Cancer

Interventions: Behavioral: Match-list intervention
Behavioral: Clinical trial match-list

First Posted Date: 2021-12-06

Last Posted Date: 2024-01-05

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 1200

Registration Number: NCT05146297

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Herbert Irving Comprehensive Cancer Care Center, New York, New York, United States

Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI

Completed

Conditions: Contrast-induced Nephropathy

Interventions: Procedure: Percutaneous Coronary Intervention

First Posted Date: 2021-11-24

Last Posted Date: 2021-11-24

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 14616

Registration Number: NCT05132062

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Pelvic Floor Disorder Education in Prenatal Care

Not Applicable

Completed

Conditions: Pelvic Floor Disorders

Interventions: Other: Education Video

First Posted Date: 2021-11-19

Last Posted Date: 2022-05-27

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 94

Registration Number: NCT05127512

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Phase 1

Active, not recruiting

Conditions: Ulcerative Colitis (Disorder)

Interventions: Drug: Hydroxychloroquine
Drug: Mesalamine

First Posted Date: 2021-11-12

Last Posted Date: 2024-03-04

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT05119140

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital, New York, New York, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy